Lee R, et al. Pulmonary aspergillosis in COVID-19

KJIM

**Supplementary Table 2. Multivariable logistic regression analysis by categorized corticosteroid use**

| Variable | Odds ratio | 95% Confidence interval |
|---|---|---|
| Total cumulative dosage (total cumulative dose over 1,000 mg) | 21.688 | 2.689–174.900 |
|     Adjusting sex | 23.624 | 2.888–193.264 |
|     Adjusting age | 15.028 | 1.786–126.475 |
|     Adjusting lymphocyte | 14.736 | 1.767–122.893 |
|     Adjusting creatinine | 19.633 | 2.313–166.680 |
|     Adjusting chronic kidney disease | 19.934 | 2.452–162.061 |
|     Adjusting COPD | 20.320 | 2.464–167.576 |
|     Adjusting chronic liver disease | 18.888 | 2.296–155.357 |
|     Adjusting diabetes | 18.959 | 2.320–154.924 |
|     Adjusting hematologic malignancy | 18.888 | 2.296–155.357 |
|     Adjusting oxygen therapy | 12.891 | 1.414–117.524 |
| Daily high-dose use (mean daily dose over 60 mg) | 17.000 | 2.112–136.845 |
|     Adjusting sex | 17.945 | 2.210–145.717 |
|     Adjusting age | 12.296 | 1.494–101.218 |
|     Adjusting lymphocyte | 11.663 | 1.410–96.467 |
|     Adjusting creatinine | 16.854 | 1.924–147.664 |
|     Adjusting chronic kidney disease | 15.983 | 1.969–129.748 |
|     Adjusting COPD | 16.434 | 1.984–136.152 |
|     Adjusting chronic liver disease | 15.079 | 1.832–124.101 |
|     Adjusting diabetes | 15.461 | 1.907–125.380 |
|     Adjusting hematologic malignancy | 15.079 | 1.832–124.101 |
|     Adjusting oxygen therapy | 10.194 | 1.172–88.641 |
| Early 7-day high-dose use (early 7-day cumulative dose over 420 mg) | 3.970 | 0.997–15.800 |
|     Adjusting sex | 4.129 | 1.026–16.619 |
|     Adjusting age | 2.641 | 0.640–10.901 |
|     Adjusting lymphocyte | 2.686 | 0.653–11.043 |
|     Adjusting creatinine | 3.331 | 0.794–13.823 |
|     Adjusting chronic kidney disease | 3.475 | 0.852–14.169 |
|     Adjusting COPD | 3.665 | 0.889–15.110 |
|     Adjusting chronic liver disease | 3.349 | 0.805–13.944 |
|     Adjusting diabetes | 3.306 | 0.807–13.535 |
|     Adjusting hematologic malignancy | 5.812 | 1.164–29.013 |
|     Adjusting oxygen therapy | 1.731 | 0.350–8.571 |
| Prolonged use (over 14 days) | 5.893 | 1.474–23.557 |
|     Adjusting sex | 6.050 | 1.504–24.342 |
|     Adjusting age | 3.661 | 0.865–15.498 |
|     Adjusting lymphocyte | 4.292 | 1.047–17.604 |
|     Adjusting creatinine | 5.612 | 1.325–23.765 |
|     Adjusting chronic kidney disease | 5.590 | 1.375–22.721 |
|     Adjusting COPD | 6.217 | 1.457–26.534 |
|     Adjusting chronic liver disease | 4.842 | 1.158–20.242 |
|     Adjusting diabetes | 4.912 | 1.191–20.252 |
|     Adjusting hematologic malignancy | 5.844 | 1.371–24.908 |
|     Adjusting oxygen therapy | 2.974 | 0.635–13.928 |

Corticosteroid doses are presented as methylprednisolone.
COPD, chronic obstructive pulmonary disease.